US · Healthcare · Biotechnology
EPS came in at -0.96 against a street estimate of -0.89 — a miss of 7.9%.
Analysts rate ArriVent BioPharma, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $44.60.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.45% |
| Hillhouse Capital Advisors, Ltd. | 8.44% |
| Orbimed Advisors, LLC | 6.50% |
| FMR Inc | 6.48% |
| BlackRock Inc | 5.43% |
| Octagon Capital Advisors LP | 4.23% |
| Novo A/S | 4.17% |
| Sofinnova Ventures | 3.64% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-22 |
| Company announcement · Q2 2026 | 2026-05-11 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Reg FD disclosure · Q1 2026 | 2026-03-17 |
| Annual report FY2025 | 2026-03-05 |
| Quarterly report · Q3 2025 | 2025-11-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ArriVent BioPharma, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.